Florencia Davel, head of LatAm operations for Bristol Myers Squibb (BMS) looks back on a successful four years in position, shaping the regional organisation into a true biopharma player in line with a global strategy shift. Davel also casts her eye over the market access scenario in LatAm, why BMS is choosing to situate clinical trials in the region, and how she hopes to capitalise on abundant opportunities to better serve patients in the coming years.
Empathetic dialogue and an understanding of our shared goals, and the value that innovation brings to health systems are critical, as is facilitating enabling infrastructure, creating better access to institutions, and fostering a holistic view of diseases from prevention to diagnosis and treatment
